Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

316 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Importance of TKI treatment duration in treatment-free remission of chronic myeloid leukemia: results of the D-FREE study.
Yoshida C, Yamaguchi H, Doki N, Murai K, Iino M, Hatta Y, Onizuka M, Yokose N, Fujimaki K, Hagihara M, Oshikawa G, Murayama K, Kumagai T, Kimura S, Najima Y, Iriyama N, Tsutsumi I, Oba K, Kojima H, Sakamaki H, Inokuchi K; Kanto CML Study Group. Yoshida C, et al. Among authors: hatta y. Int J Hematol. 2023 May;117(5):694-705. doi: 10.1007/s12185-023-03549-3. Epub 2023 Feb 4. Int J Hematol. 2023. PMID: 36739328 Free PMC article. Clinical Trial.
High-risk Combinations of Additional Chromosomal Abnormalities in Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia: JALSG Ph+ALL TKI-SCT Study.
Nishiwaki S, Sugiura I, Fujisawa S, Hatta Y, Atsuta Y, Doki N, Kurahashi S, Ueda Y, Dobashi N, Maeda T, Taniguchi Y, Tanaka M, Kako S, Ichinohe T, Fukuda T, Ohtake S, Ishikawa Y, Kiyoi H, Matsumura I, Miyazaki Y. Nishiwaki S, et al. Among authors: hatta y. Hemasphere. 2023 Jun 8;7(6):e899. doi: 10.1097/HS9.0000000000000899. eCollection 2023 Jun. Hemasphere. 2023. PMID: 37475881 Free PMC article. No abstract available.
Changes in chronic myeloid leukemia treatment modalities and outcomes after introduction of second-generation tyrosine kinase inhibitors as first-line therapy: a multi-institutional retrospective study by the CML Cooperative Study Group.
Iriyama N, Iwanaga E, Kimura Y, Watanabe N, Ishikawa M, Nakayama H, Sato E, Tabayashi T, Mitsumori T, Takaku T, Nakazato T, Tokuhira M, Fujita H, Ando M, Hatta Y, Kawaguchi T. Iriyama N, et al. Among authors: hatta y. Int J Hematol. 2024 Jul;120(1):60-70. doi: 10.1007/s12185-024-03758-4. Epub 2024 Apr 8. Int J Hematol. 2024. PMID: 38587692
Nelarabine-combined chemotherapy improves outcome of T-cell acute lymphoblastic leukemia but shows more severe neurotoxicity: JALSG T-ALL213-O.
Hayakawa F, Mori N, Imai K, Yokoyama Y, Katsuoka Y, Saito T, Murayama T, Yamazaki E, Sato S, Atsuta Y, Ishikawa Y, Sakaida E, Hatta Y, Matsumura I, Miyazaki Y, Kiyoi H; Japan Adult Leukemia Study Group (JALSG). Hayakawa F, et al. Among authors: hatta y. Cancer Sci. 2024 Nov 21. doi: 10.1111/cas.16405. Online ahead of print. Cancer Sci. 2024. PMID: 39572007 Free article.
Clinical management of second-generation tyrosine kinase inhibitor therapy in patients with newly diagnosed chronic myeloid leukemia in the chronic phase, focusing on age and dose effects.
Tokuhira M, Kimura Y, Tabayashi T, Watanabe N, Tsuchiya S, Takaku T, Iriyama N, Sato E, Nakazato T, Mitsumori T, Ishikawa M, Fujita H, Kizaki M, Ando M, Hatta Y, Iwanaga E, Kawaguchi T. Tokuhira M, et al. Among authors: hatta y. Int J Hematol. 2023 Aug;118(2):210-220. doi: 10.1007/s12185-023-03606-x. Epub 2023 May 2. Int J Hematol. 2023. PMID: 37129800
Macrophage depletion using clodronate liposomes reveals latent dysfunction of the hematopoietic microenvironment associated with persistently imbalanced M1/M2 macrophage polarization in a mouse model of hemophagocytic lymphohistiocytosis.
Koike T, Miura K, Hatta Y, Nakamura H, Hirabayashi Y, Yuda M, Harada T, Hirai S, Tsuboi I, Aizawa S. Koike T, et al. Among authors: hatta y. Ann Hematol. 2023 Dec;102(12):3311-3323. doi: 10.1007/s00277-023-05425-w. Epub 2023 Sep 1. Ann Hematol. 2023. PMID: 37656190
Differential clinical impact of letermovir prophylaxis according to graft sources: a KSGCT multicenter retrospective analysis.
Toya T, Mizuno K, Sakurai M, Kato J, Mori T, Doki N, Masuda S, Aotsuka N, Tsukamoto S, Sakaida E, Nakajima Y, Fujisawa S, Machida S, Aoyama Y, Yokoyama H, Shono K, Hatta Y, Usuki K, Kataoka K, Kanda Y. Toya T, et al. Among authors: hatta y. Blood Adv. 2024 Mar 12;8(5):1084-1093. doi: 10.1182/bloodadvances.2023010735. Blood Adv. 2024. PMID: 38330190 Free PMC article.
316 results